Literature DB >> 15731375

Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model.

Clare Horkan1, Kshitij Dalal, Jeffrey A Coderre, Jingli Liu Kiger, Damian E Dupuy, Sabina Signoretti, Elkan F Halpern, S Nahum Goldberg.   

Abstract

PURPOSE: To determine whether use of combined radiofrequency (RF) ablation and external-beam radiation therapy increases end-point survival beyond that with either RF ablation or radiation therapy alone in an animal tumor model.
MATERIALS AND METHODS: With a protocol approved by the institutional animal care and use committee, R3230 mammary adenocarcinoma (12.5 mm +/- 0.6 [standard deviation]) was implanted subcutaneously into 107 female Fischer 344 rats. Initially, 42 tumors were randomized into four treatment groups: (a) RF ablation (70 degrees C for 5 minutes) alone, (b) RF ablation followed by radiation therapy with a total dose of 20 Gy, (c) 20-Gy radiation alone, and (d) no treatment. Another 19 tumors were randomized to receive (e) RF ablation (70 degrees C for 5 minutes) followed by 5-Gy radiation, (f) 5-Gy radiation alone, or (g) no treatment. Animals were followed up until survival end point (either until tumor growth to 30 mm in diameter, or for 120 days if no tumor was seen in mammary fat pad or chest wall). Results were analyzed with the Kaplan-Meier method. Histopathologic analysis was performed in 15 additional tumors at survival end point and 18 other representative tumors at other specified end points.
RESULTS: Combined RF ablation and 20-Gy radiation resulted in complete local control in nine (82%) of 11 tumors, compared with one (9%) of 11 tumors treated with RF ablation alone and one (17%) of six treated with RF ablation and 5-Gy radiation (P < .001). No local control was achieved in rats with radiation therapy alone or in controls. Median end-point survival was 12 days for controls, 20 days with RF ablation or 5-Gy radiation alone, 30 days with RF ablation plus 5-Gy radiation, 40 days with 20-Gy radiation alone, and 120 days with RF ablation plus 20-Gy radiation. Mean end-point survival was 13 days +/- 5 (standard deviation) for the control group, 34 days +/- 31 with RF ablation alone, and 43 days +/- 16 with 20-Gy radiation alone. Mean survival was significantly greater with 20-Gy radiation and RF ablation combined: 94 days +/- 34 (P < .001 compared with all other groups). Mean survival for rats that received 5-Gy radiation with RF ablation versus without was 46 days +/- 37 versus 24 days +/- 11, respectively.
CONCLUSION: Combined RF ablation and external-beam radiation therapy increased animal survival compared with that with either of the treatments alone or with no treatment. (c) RSNA, 2005.

Entities:  

Mesh:

Year:  2005        PMID: 15731375     DOI: 10.1148/radiol.2351040269

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

Review 1.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

2.  Surrounding rim formation and reduction in size after radiofrequency ablation for primary breast cancer.

Authors:  Takeshi Nagashima; Masahiro Sakakibara; Takafumi Sangai; Toshiki Kazama; Hiroshi Fujimoto; Masaru Miyazaki
Journal:  Jpn J Radiol       Date:  2009-06-25       Impact factor: 2.374

Review 3.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

4.  Effect of thermal dose on heat shock protein expression after radio-frequency ablation with and without adjuvant nanoparticle chemotherapies.

Authors:  Marwan Moussa; S Nahum Goldberg; Gaurav Kumar; Tatyana Levchenko; Vladimir Torchilin; Muneeb Ahmed
Journal:  Int J Hyperthermia       Date:  2016-09-06       Impact factor: 3.914

Review 5.  Thermal ablation of lung tumors.

Authors:  P David Sonntag; J Louis Hinshaw; Meghan G Lubner; Christopher L Brace; Fred T Lee
Journal:  Surg Oncol Clin N Am       Date:  2011-04       Impact factor: 3.495

Review 6.  Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.

Authors:  Muneeb Ahmed; Marwan Moussa; S Nahum Goldberg
Journal:  Chem Phys Lipids       Date:  2011-12-14       Impact factor: 3.329

7.  Combination radiofrequency (RF) ablation and IV liposomal heat shock protein suppression: reduced tumor growth and increased animal endpoint survival in a small animal tumor model.

Authors:  Wei Yang; Muneeb Ahmed; Beenish Tasawwar; Tatynana Levchenko; Rupa R Sawant; Vladimir Torchilin; S Nahum Goldberg
Journal:  J Control Release       Date:  2011-12-30       Impact factor: 9.776

8.  Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?

Authors:  Wei Yang; Muneeb Ahmed; Mostafa Elian; El-Shymma A Hady; Tatyana S Levchenko; Rupa R Sawant; Sabina Signoretti; Michael Collins; Vladimir P Torchilin; S Nahum Goldberg
Journal:  Radiology       Date:  2010-09-21       Impact factor: 11.105

9.  Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model.

Authors:  Wei Yang; Muneeb Ahmed; Beenish Tasawwar; Tatyana Levchenko; Rupa R Sawant; Michael Collins; Sabina Signoretti; Vladimir Torchilin; S Nahum Goldberg
Journal:  Int J Hyperthermia       Date:  2011       Impact factor: 3.914

10.  Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways.

Authors:  Stephanie A Solazzo; Muneeb Ahmed; Rachel Schor-Bardach; Wei Yang; Geoffrey D Girnun; Syed Rahmanuddin; Tatyana Levchenko; Sabina Signoretti; Douglas R Spitz; Vladimir Torchilin; S Nahum Goldberg
Journal:  Radiology       Date:  2010-02-16       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.